Care Coordination and Transition Strategies for CAR-T Therapy

Opinion
Video

Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.

Video content above is prompted by the following:

  • Describe your institution’s approach to the co-management and co-monitoring of patients receiving CAR-T therapy, particularly in the transition back to the community setting.
  • Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for CAR-T patients?
  • What are the most common challenges you have encountered in the CAR-T referral process, and how have you addressed them at your institution?
  • What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR-T therapy?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content